Viruses As Vaccine Vectors for Infectious Diseases and Cancer

Overview

Journal Nat Rev Microbiol

Specialties Infectious Diseases
Microbiology

Date 2009 Dec 8

PMID 19966816

Citations 179

Authors

Simon J Draper

Jonathan L Heeney

Affiliations

Soon will be listed here.

Abstract

Recent developments in the use of viruses as vaccine vectors have been facilitated by a better understanding of viral biology. Advances occur as we gain greater insight into the interrelationship of viruses and the immune system. Viral-vector vaccines remain the best means to induce cellular immunity and are now showing promise for the induction of strong humoral responses. The potential benefits for global health that are offered by this field reflect the scope and utility of viruses as vaccine vectors for human and veterinary applications, with targets ranging from certain types of cancer to a vast array of infectious diseases.

Citing Articles

Evaluating Antigen- and Vector-Specific Immune Responses of a Recombinant Pichinde Virus-Based Vaccine Expressing the Lymphocytic Choriomeningitis Virus Nucleoprotein.

Cain M, Huang Q, Sanchez S, Ly H, Liang Y Vaccines (Basel). 2025; 12(12.

PMID: 39772112 PMC: 11680116. DOI: 10.3390/vaccines12121450.

Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.

Rong Y, Ning Y, Zhu J, Feng P, Zhu W, Zhao X Mol Biomed. 2024; 5(1):39.

PMID: 39306655 PMC: 11416448. DOI: 10.1186/s43556-024-00202-1.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.

Kamboj A, Dumka S, Saxena M, Singh Y, Kaur B, da Silva S Viruses. 2024; 16(6).

PMID: 38932126 PMC: 11209531. DOI: 10.3390/v16060833.

Recent and advanced nano-technological strategies for COVID-19 vaccine development.

Nwagwu C, Ugwu C, Ogbonna J, Onugwu A, Agbo C, Echezona A Methods Microbiol. 2024; 50:151-188.

PMID: 38620863 PMC: 9015106. DOI: 10.1016/bs.mim.2022.03.001.

References

Moss B, Smith G, Gerin J, Purcell R . Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984; 311(5981):67-9. DOI: 10.1038/311067a0. View

Heeney J, Koopman G, Rosenwirth B, Bogers W, van Dijk J, Nieuwenhuis I . A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J Med Primatol. 2000; 29(3-4):268-73. DOI: 10.1034/j.1600-0684.2000.290320.x. View

Kaufman H, Taback B, Sherman W, Kim D, Shingler W, Moroziewicz D . Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009; 7:2. PMC: 2631474. DOI: 10.1186/1479-5876-7-2. View

Staib C, Kisling S, Erfle V, Sutter G . Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol. 2005; 86(Pt 7):1997-2006. DOI: 10.1099/vir.0.80646-0. View

Lamoreaux L, Roederer M, Koup R . Intracellular cytokine optimization and standard operating procedure. Nat Protoc. 2007; 1(3):1507-16. DOI: 10.1038/nprot.2006.268. View

Geiben-Lynn R, Greenland J, Frimpong-Boateng K, Letvin N . Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin Vaccine Immunol. 2008; 15(4):691-6. PMC: 2292663. DOI: 10.1128/CVI.00418-07. View

Tewalt E, Grant J, Granger E, Palmer D, Heuss N, Gregerson D . Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. PLoS Pathog. 2009; 5(5):e1000457. PMC: 2680035. DOI: 10.1371/journal.ppat.1000457. View

Hodge J, Guha C, Neefjes J, Gulley J . Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008; 22(9):1064-70. PMC: 3474236. View

Ludwig H, Mages J, Staib C, Lehmann M, Lang R, Sutter G . Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes. J Virol. 2005; 79(4):2584-96. PMC: 546556. DOI: 10.1128/JVI.79.4.2584-2596.2005. View

10.

Alejo A, Ruiz-Arguello M, Ho Y, Smith V, Saraiva M, Alcami A . A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A. 2006; 103(15):5995-6000. PMC: 1458686. DOI: 10.1073/pnas.0510462103. View

11.

Meeusen E, Walker J, Peters A, Pastoret P, Jungersen G . Current status of veterinary vaccines. Clin Microbiol Rev. 2007; 20(3):489-510, table of contents. PMC: 1932753. DOI: 10.1128/CMR.00005-07. View

12.

Mooij P, Balla-Jhagjhoorsingh S, Koopman G, Beenhakker N, van Haaften P, Baak I . Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol. 2008; 82(6):2975-88. PMC: 2258966. DOI: 10.1128/JVI.02216-07. View

13.

Xiang Z, Gao G, Reyes-Sandoval A, Cohen C, Li Y, Bergelson J . Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002; 76(6):2667-75. PMC: 135983. DOI: 10.1128/jvi.76.6.2667-2675.2002. View

14.

Draper S, Goodman A, Biswas S, Forbes E, Moore A, Gilbert S . Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe. 2009; 5(1):95-105. PMC: 2663714. DOI: 10.1016/j.chom.2008.12.004. View

15.

Hodge J, Poole D, Aarts W, Yafal A, Gritz L, Schlom J . Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 2003; 63(22):7942-9. View

16.

Forbes E, Sander C, Ronan E, McShane H, Hill A, Beverley P . Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol. 2008; 181(7):4955-64. PMC: 2867031. DOI: 10.4049/jimmunol.181.7.4955. View

17.

Draper S, Moore A, Goodman A, Long C, Holder A, Gilbert S . Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008; 14(8):819-21. PMC: 4822545. DOI: 10.1038/nm.1850. View

18.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

19.

Shen X, Wong S, Buck C, Zhang J, Siliciano R . Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol. 2002; 169(8):4222-9. DOI: 10.4049/jimmunol.169.8.4222. View

20.

Tatsis N, Tesema L, Robinson E, Giles-Davis W, McCoy K, Gao G . Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2005; 13(5):421-9. DOI: 10.1038/sj.gt.3302675. View